Period
recent search
Showing: 1 – 05 of 171 Regulated Information
09 February 2023
09 February 2023
LinkedIn
Facebook
Ipsen presents strong full-year 2022 results and guidance for 2023
Paris (France), 9 February 2023
06 January 2023
06 January 2023
LinkedIn
Ipsen – Half year statement – 2022 12 31
This article or press release has no online content. Please download the associated documents for more information.
06 January 2023
06 January 2023
LinkedIn
Voting rights on 31 December 2022
This article or press release has no online content. Please download the associated documents for more information.
14 December 2022
14 December 2022
LinkedIn
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
PARIS, FRANCE, 23 December 2022 – The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation (heterotopic ossification) in people…
09 December 2022
09 December 2022
LinkedIn
Voting rights on 30 November 2022
This article or press release has no online content. Please download the associated documents for more information.